

5 **Name of Journal:** *World Journal of Clinical Cases*

Manuscript NO: 54377

Manuscript Type: CASE REPORT

Significant benefits of **pembrolizumab** in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report

Chen P *et al.* Pembrolizumab for refractory advanced PSC

Ping Chen, Min Yu, Ji-Liang Zhang, Wei-Yong Chen, Li Zhu, Yue Song, Cheng-Yi Jiang, Shuang Zhang

Abstract

BACKGROUND

Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer (NSCLC), is poorly differentiated and highly aggressive. Treatment is limited, and the prognosis is poor. Pembrolizumab is an anti-programmed death (PD)-1 antibody with good efficacy in NSCLC. Recent studies have demonstrated that PD-ligand 1 (PD-L1) overexpression is common in PSCs, which suggests that anti-PD-L1 treatment is an ideal option. However, the response to pembrolizumab in PSC has not been studied.

CASE SUMMARY

Match Overview

Match Number	Source	Words	Similarity
1	Crossref	30 words	1%
	Takehiro Uemura, Toyoaki Hida. "Durvalumab showed long and durable effects after chemoradiotherapy in stage III n...		
2	Internet	30 words	1%
	crawled on 05-May-2015 www.ncbi.nlm.nih.gov		
3	Internet	29 words	1%
	crawled on 07-May-2020 www.wjgnet.com		
4	Crossref	25 words	1%
	Yan Zhang, Hui-Min Chen, Yong-Mei Liu, Feng Peng, Min Yu, Wei-Ya Wang, Heng Xu, Yong-Sheng Wang, You Lu. "Sig		
5	Internet	15 words	<1%
	crawled on 29-Mar-2020 f6publishing.blob.core.windows.net		
6	Internet	13 words	<1%
	crawled on 11-Jan-2020 www.dovepress.com		

Significant benefits of pembrolizumab in treating refractory ad'



ALL

IMAGES

VIDEOS

27,300 Results

Any time ▾

[Pembrolizumab - emerging treatment of pulmonary ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962068>

Jan 06, 2020 · Core tip: **Pulmonary sarcomatoid carcinoma** (PSC) is classified as a rare, aggressive subtype of non-small-cell lung cancer. In recent years, **pembrolizumab**, a humanized monoclonal IgG-kappa isotype antibody against the programmed death-1 receptor, has become the first-line **treatment** for NSCLE with programmed death-ligand-1 (PD-L1) expression on at least ...

Author: Emanuela Cimpeanu, Jibrán Ahmed... **Publish Year:** 2020

[Pembrolizumab - emerging treatment of pulmonary ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/31970174>

Jan 06, 2020 · BACKGROUND: Few studies have addressed the efficacy of **pembrolizumab** in **pulmonary sarcomatoid carcinoma** (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer. **CASE SUMMARY:** We **report** the **case** of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with ...

Author: Emanuela Cimpeanu, Jibrán Ahmed... **Publish Year:** 2020

[Single pembrolizumab treatment causing profound durable ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586952>

Schrock et al. reported the case of a durable response to **pembrolizumab** in a **patient with pulmonary pleomorphic carcinoma**. This patient had a high TMB as well as positive PD-L1 staining with a tumor proportion score of 80%, and they suggested that **pembrolizumab** may be **beneficial** in this population .

Cited by: 2 **Author:** Hirokazu Tokuyasu, Soichiro Ishikawa, ...

Publish Year: 2019



ALL IMAGES VIDEOS MAPS NEWS SHOPPING

27,300 Results Any time ▾

Pembrolizumab - emerging treatment of pulmonary ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962068>

Jan 06, 2020 · Core tip: **Pulmonary sarcomatoid carcinoma** (PSC) is classified as a rare, aggressive subtype of non-small-cell lung cancer. In recent years, **pembrolizumab**, a humanized monoclonal IgG-kappa isotype antibody against the programmed death-1 receptor, has become the first-line **treatment** for NSCLE with programmed death-ligand-1 (PD-L1) expression on at least 50% of tumor cells.

Author: Emanuela Cimpeanu, Jibrán Ahmed, ... **Publish Year:** 2020

Pembrolizumab - emerging treatment of pulmonary ...

<https://www.ncbi.nlm.nih.gov/pubmed/31970174>

Jan 06, 2020 · BACKGROUND: Few studies have addressed the efficacy of **pembrolizumab** in **pulmonary sarcomatoid carcinoma** (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer. **CASE SUMMARY:** We **report** the **case** of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with ...

Author: Emanuela Cimpeanu, Jibrán Ahmed, ... **Publish Year:** 2020

Single pembrolizumab treatment causing profound durable ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586952>

Schrock et al. reported the case of a durable response to **pembrolizumab** in a **patient with pulmonary pleomorphic carcinoma**. This patient had a high TMB as well as positive PD-L1 staining with a tumor proportion score of 80%, and they suggested that **pembrolizumab** may be **beneficial** in this population .

Cited by: 2 **Author:** Hirokazu Tokuyasu, Soichiro Ishikawa, Hi...

Publish Year: 2019

Pembrolizumab - emerging treatment of pulmonary ...

<https://www.wjgnet.com/2307-8960/coretip/v8/i1/97.htm>

Core tip: **Pulmonary sarcomatoid carcinoma** (PSC) is classified as a rare, aggressive subtype of non-small-cell lung cancer. In recent years, **pembrolizumab**, a humanized monoclonal IgG-kappa isotype

[v.ncbi.nlm.nih.gov/pmc/articles/PMC6962068/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962068/) antibody against the programmed death-1 receptor, has become the first-line **treatment** for NSCLE with